Finland· FI-REL-REL10959

Bovalto Ibraxion

A naudan rinotrakeiittivirus -rokote product containing rhinotracheitisvirus (ibr), ge removed, inactivated, registered in Finland by Merial S.A.S.

ATC QI02AA03

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedBovalto IbraxionATCQI02AA03REGISTER NO.FI-REL-REL10959PACKS LISTED0CHECKEDSeptember 27, 2026

The record

At a glance

Fimea (Finland)
Active substance
Rhinotracheitisvirus (IBR), gE removed, inactivated
Manufacturer
Merial S.A.S
Country
Finland (FI)
ATC code
QI02AA03
ATC class
Naudan rinotrakeiittivirus -rokote
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/eb0ee236-1f85-4ac8-8f68-5deaf14f3100
GET /v1/drugs/eb0ee236-1f85-4ac8-8f68-5deaf14f3100?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektioneste, emulsio",
  "route": "Ihon alle",
  "ddd_unit": null,
  "strength": null,
  "atc_label": "Naudan rinotrakeiittivirus -rokote",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/2/99/17/01-06",
  "fimea_rel_id": "REL10959",
  "authorised_at": "2000-03-09"
}

See everything about rhinotracheitisvirus (ibr), ge removed, inactivated.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.